FDA Approved: YERVOY — Supplemental Application (E.R. Squibb & Sons, L.L.C.)

View source ↗

Summary

FDA announces a supplemental application for YERVOY (ipilimumab) submitted by E.R. Squibb & Sons, L.L.C., relating to labeling changes for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• Yervoy (ipilimumab)

Snippet

SUPPL AP for YERVOY (IPILIMUMAB)